Skip to Content

Newsroom

Adjuvant Radiation Therapy for Axilary Lymph Node Metastases from Malignant Melanoma May be Superior to Surgery Alo

Adjuvant Radiation Therapy for Axilary Lymph Node Metastases from Malignant Melanoma May be Superior to Surgery Alone
Results from the 43rd Annual American Society for Therapeutic Radiology and Oncology (ASTRO),November 2001
M. D. Anderson News Release 11/28/01

 

Radiation therapy for lymph node metastases from malignant melanoma may be superior to surgery alone when high-risk features are present, according to a study led by Dr. Matthew T. Ballo, assistant professor of radiation oncology at M. D. Anderson Cancer Center.

The medical records of 89 patients with axillary lymph node metastases from malignant melanoma were retrospectively reviewed. All but two of the patients were referred because their dissections revealed histopathological features believed to predict a 30-50% risk of recurrence.

"Adjuvant radiation therapy using a hypofractionated regimen (larger radiation doses delivered over a shorter period of time) results in an 87% five-year axillary control rate," Dr. Ballo said. "This appears superior to the 50-70% local control achieved with surgery alone for lymph node metastases from melanoma."

11/28/01


© 2014 The University of Texas MD Anderson Cancer Center